News & Updates

Patients with severe COVID-19 requiring mechanical ventilation are 16 times more likely to develop ventricular tachycardia (V-tach) within 6 months following discharge compared with matched controls without severe infection in a Swedish case-control study presented at EHRA 2023.

Ten-day treatment with vonoprazan 20 mg twice/day plus amoxicillin 750 mg four times/day (VHA-dual) as a first-line therapy for Helicobacter pylori infection results in satisfactory eradication rate of >90 percent, fewer adverse events (AEs), and similar adherence when compared with bismuth quadruple therapy (B-quadruple), results of a study have shown.

Sleep disruption following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness in the CircCOVID cohort sub-study presented at ECCMID 2023.

Individuals who have contracted COVID-19 at increased risk of developing irritable bowel syndrome (IBS) compared with those who have not been infected, as reported in a study.

In vaccinated adults with COVID-19 who are at higher risk of adverse outcomes, treatment with molnupiravir in addition to usual care falls short of reducing the rates of hospitalizations and deaths, as shown by the results of the PANORAMIC study.

In a functional assessment of post-COVID long-term sequelae, individuals suffering from long COVID (having at least one symptom of post-COVID-19 syndrome) had poorer quality of life (QoL) than those unaffected by the syndrome.